CVS Health’s 2024 Operating Income Reduced by up to $1 Billion Because of Low MA Star Ratings
The company said 21% of its Medicare Advantage members are in plans with 2023 ratings of 4.0 or above, a steep decline from the 2023 star ratings.
CVS Health’s operating will take up to a $1 billion hit in 2024 because low Medicare Advantage star ratings, the company said in a Securities and Exchange Commission (SEC) filing today.
Just 21% of the people in the company’s Medicare Advantage plans were in plans with 2023 star rating of 4.0 or greater compared with 87% in the 2022 star ratings, the SEC filings said.
The Centers of Medicare and Medicaid Services (CMS) uses its star ratings to determine which Medicare Advantage plans qualify for quality bonuses. Plans with a rating of 4.0 or more can receive the quality bonuses to their premiums
The CVS’ 2024 operating income is affected by the 2023 ratings because CMS uses the 2023 ratings to determine eligibility for the 2024 bonuses.
Modern Healthcare was the first to report on the SEC filing.
The star ratings are based on measurements of Medicare Advantage’s coverage of preventive care and chronic disease management as well as customer satisfaction.
In the SEC filing, CVS said the main driver of the precipitous drop in members covered with plans eligible for bonus payments was a 1-star decrease in the company’s Aetna National preferred provider organization.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
